Brokers Set Expectations for Cerus FY2026 Earnings

Cerus Co. (NASDAQ:CERS - Free Report) - Analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for shares of Cerus in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst R. Osborn forecasts that the biotechnology company will post earnings of $0.00 per share for the year. Cantor Fitzgerald has a "Overweight" rating and a $4.00 price objective on the stock. The consensus estimate for Cerus' current full-year earnings is ($0.08) per share.

Cerus (NASDAQ:CERS - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.05) by $0.01. The firm had revenue of $43.24 million for the quarter, compared to analyst estimates of $47.44 million. Cerus had a negative return on equity of 40.55% and a negative net margin of 11.60%.

Cerus Trading Down 2.0%

Shares of CERS traded down $0.03 during mid-day trading on Tuesday, hitting $1.44. 1,099,599 shares of the company's stock traded hands, compared to its average volume of 1,305,169. The business's 50-day moving average price is $1.32 and its 200-day moving average price is $1.55. Cerus has a 1 year low of $1.12 and a 1 year high of $2.54. The company has a quick ratio of 1.92, a current ratio of 2.59 and a debt-to-equity ratio of 1.19. The firm has a market capitalization of $275.27 million, a P/E ratio of -13.09 and a beta of 1.55.

Insider Transactions at Cerus

In related news, insider Richard J. Benjamin sold 18,949 shares of the business's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $1.45, for a total transaction of $27,476.05. Following the completion of the transaction, the insider now directly owns 715,850 shares in the company, valued at approximately $1,037,982.50. The trade was a 2.58% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Kevin Dennis Green sold 23,147 shares of the stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $1.45, for a total transaction of $33,563.15. Following the completion of the sale, the chief financial officer now directly owns 912,607 shares of the company's stock, valued at approximately $1,323,280.15. This trade represents a 2.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 143,167 shares of company stock valued at $207,592 in the last ninety days. 5.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Cerus

Several large investors have recently made changes to their positions in the business. Rhumbline Advisers raised its stake in Cerus by 5.5% during the 1st quarter. Rhumbline Advisers now owns 251,907 shares of the biotechnology company's stock valued at $350,000 after purchasing an additional 13,112 shares during the period. Acadian Asset Management LLC grew its holdings in Cerus by 112.5% during the 1st quarter. Acadian Asset Management LLC now owns 1,898,621 shares of the biotechnology company's stock valued at $2,637,000 after buying an additional 1,005,079 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in Cerus during the 1st quarter valued at approximately $32,000. Millennium Management LLC raised its position in shares of Cerus by 12.0% during the first quarter. Millennium Management LLC now owns 3,222,327 shares of the biotechnology company's stock valued at $4,479,000 after buying an additional 344,395 shares during the last quarter. Finally, AQR Capital Management LLC lifted its holdings in shares of Cerus by 291.6% in the first quarter. AQR Capital Management LLC now owns 1,429,062 shares of the biotechnology company's stock worth $1,986,000 after buying an additional 1,064,133 shares in the last quarter. 78.37% of the stock is currently owned by hedge funds and other institutional investors.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.